ERNA Stock Eterna Therapeutics (ERNA, $0.25) Aroon Indicator entered a Downtrend on December 20, 2024.

GET DAILY SIGNALS

Get AI intraday signals

ERNA - Eterna Therapeutics

Aroon signal

View

Odds of DOWN Trend

Price: $0.2501

Daily change: +$0.0026 (+1.05%)

Daily volume: 425.2K

Capitalization: $12.8M

Industry: Biotechnology

ERNA in -9.41% downward trend, sliding for three consecutive days on December 17, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ERNA declined for three days, in of 367 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ERNA entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ERNA just turned positive on December 12, 2024. Looking at past instances where ERNA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where ERNA advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

ERNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.847) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). ERNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (2.263) is also within normal values, averaging (256.215).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ERNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.